The twenty-first century is defined by a dual revolution: a demographic shift toward an aging population and a scientific paradigm shift that reframes aging itself as a treatable biological process. The emerging “Longevity Economy” moves beyond simply managing age-related decline, instead focusing on interventions designed to extend healthspan by targeting the fundamental mechanisms of aging. This chapter explores the key investment opportunities within this landscape, from biotechnology ventures applying geroscience and AI-driven diagnostics to Age-Tech platforms enhancing autonomy. Special emphasis is placed on the economic and scientific imperative of investing in women’s health, an area historically underfunded yet critical to systemic longevity. By analyzing case studies and emerging technologies, I illustrate how an integrated investment thesis, one that values long-range impact and first-principles science, is essential for catalyzing a future where extended healthspan and vitality redefine our collective prosperity.